## **Emcure**

To,

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051

Script Symbol: EMCURE

BSE Limited
P J Towers,
Dalal Street,
Mumbai- 400 001

Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

<u>Subject:</u> Board Meeting intimation for approval of unaudited financial results (standalone and consolidated) for the quarter and half-year ended September 30, 2025

Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform that a meeting of the Board of Directors of the Company is scheduled to be held on **Tuesday**, **November 11**, 2025 *inter-alia* to consider and approve the unaudited financial results (standalone and consolidated) for the quarter and half-year ended September 30, 2025.

The trading window for dealing in securities of the Company by the Designated Persons and their relatives has been already closed from October 01, 2025, as communicated earlier vide our letter no. EPL/CS/SE/0072/2025 dated September 26, 2025 and shall remain closed till 48 hours after the declaration of the unaudited financial results i.e. till November 13, 2025, in terms of the Company's Code of Conduct for regulating, monitoring and reporting of insider trading in the securities of the Company, framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended.

You are requested to take the above information on your records.

Thanking you,

For Emcure Pharmaceuticals Limited

Chetan Sharma Company Secretary & Compliance Officer Membership Number: F8352